Last reviewed · How we verify
Radiation Therapy Oncology Group — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
4 Phase 3
15 Phase 2
3 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| LHRH | LHRH | marketed | Other | |||
| AA | AA | marketed | Oncology | |||
| Biafine cream | Biafine cream | marketed | ||||
| Eulexin | Eulexin | marketed | Other | |||
| CCNU | CCNU | phase 3 | Nitrosourea alkylating agent | DNA (non-selective alkylating agent) | Oncology | |
| Anti-androgen | Anti-androgen | phase 3 | ||||
| concurrent temozolomide | concurrent temozolomide | phase 3 | alkylating agent | Oncology | ||
| Sm-153 | Sm-153 | phase 3 | Oncology |
Therapeutic area mix
- Oncology · 6
- Other · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AstraZeneca · 2 shared drug classes
- Air Force Military Medical University, China · 2 shared drug classes
- Shandong Cancer Hospital and Institute · 2 shared drug classes
- Akeso · 1 shared drug class
- Associazione Volontari Pazienti Oncologici · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Barts & The London NHS Trust · 1 shared drug class
- Alliance for Clinical Trials in Oncology · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Radiation Therapy Oncology Group:
- Radiation Therapy Oncology Group pipeline updates — RSS
- Radiation Therapy Oncology Group pipeline updates — Atom
- Radiation Therapy Oncology Group pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Radiation Therapy Oncology Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/radiation-therapy-oncology-group. Accessed 2026-05-17.